Structural basis for the bypass of the major oxaliplatin–DNA adducts by human DNA polymerase η

Volume: 476, Issue: 4, Pages: 747 - 758
Published: Feb 28, 2019
Abstract
Oxaliplatin, together with cisplatin, is among the most important drugs used in cancer chemotherapy. Oxaliplatin, which contains a bulky diaminocyclohexane (DACH) moiety, kills cancer cells mainly by producing (DACH)Pt-GpG intrastrand cross-links that impede transcription. The Pt-GpG tolerance by translesion DNA synthesis (TLS) polymerases contributes to the resistance of tumors to platinum-based chemotherapy. In particular, human DNA polymerase...
Paper Details
Title
Structural basis for the bypass of the major oxaliplatin–DNA adducts by human DNA polymerase η
Published Date
Feb 28, 2019
Volume
476
Issue
4
Pages
747 - 758
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.